Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a financially strong company with a promising pipeline of treatments for various cancers, including NSCLC, PDAC, low-grade serous ovarian cancer, and KRAS-mutant and advanced solid tumors. The company's current drug under development for low-grade serous ovarian cancer has shown positive preliminary results and minimal side effects, while also showing potential for treating lung cancer and brain metastases. However, as a clinical-stage company, there are inherent risks involved, and investors should continue to closely monitor for any updates on the company's latest developments and trials.

Bears say

Verastem is facing mixed safety concerns from its GenFleet dataset, as its clinical trials have shown an alarming rate of grade 3/4 treatment-related adverse events (TRAEs), including gastrointestinal issues, anemia, and lowered white blood cell count. Additionally, the company's lead program, avutometinib + defactinib, may face challenges in delivering durable suppression of the RAS/RAF/MEK/ERK pathway, a known oncogenic driver in RAS-mutant solid tumors, due to the activation of focal adhesion kinase. This may limit the clinical benefits of the combination therapy and hinder the company's growth potential.

Verastem (VSTM) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.